Korea Stem Cell Co. Ltd.'s stock price headed directly to the lower limit (the lowest daily price limit) as soon as the market opened on the 18th. This was because it was revealed that the company could not secure efficacy in the Phase 3 clinical trial of the amyotrophic lateral sclerosis stem cell therapy, Neuronata-R.
Korea Stem Cell Co. Ltd. shares were traded at 10,330 won on the KOSDAQ market at 9:18 a.m. that day. Right after the market opened, the stock price plummeted by 29.97% (4,420 won) compared to the previous day. This was influenced by the company's public announcement of topline data, which includes some key indicators disclosed before the release of final clinical results.
Korea Stem Cell Co. Ltd. conducted the Neuronata-R clinical trial involving a total of 126 participants, and the results showed that they could not demonstrate efficacy between the test group and the control group in the efficacy evaluation, and it was statistically non-significant as well. Korea Stem Cell Co. Ltd. plans to disclose additional test results after receiving the Clinical Study Report (CSR) in the first half of 2025.
Korea Stem Cell Co. Ltd. has shown a sharp upward trend in stock prices while announcing the topline data this month. On the 11th, the price jumped from 11,030 won to the previous day's closing price of 14,750 won. During trading, it even recorded a one-year high of 15,610 won.